Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016102 | 0.80 | CYP19A1 (0.49) | CYP19A1MAPTMEN1KMT2A | |
| Finrozole SCHEMBL1649445 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Finrozole SCHEMBL2138489 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Finrozole SCHEMBL1658815 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL3987586 | 0.71 | CYP19A1 (0.54) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8104979 | 0.70 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL11095315 | 0.68 | MEN1 (0.54) | CYP19A1MAPTMEN1KMT2A | |
| SCHEMBL6204190 | 0.68 | MAPT (0.57) | CYP19A1MAPTMEN1KMT2A | |
| SCHEMBL11081016 | 0.68 | KMT2A (0.59) | CYP19A1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL8769060 | 0.67 | CYP19A1 (0.44) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674626-B1 | SELECTIVE AROMATASE INHIBITING COMPOUNDS | RISTO ARVO SAKARI LAMMINTAUSTA (FI) | 2000-07-19 | — | — | EP | claimed |
| EP-0674626-A1 | NOVEL SELECTIVE AROMATASE INHIBITING COMPOUNDS | ORION-YHTYMÄ OY (FI) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013645-A1 | NOVEL SELECTIVE AROMATASE INHIBITING COMPOUNDS | Orion-Yhtymä Oy (FI) | 1994-06-23 | — | — | WO | claimed |
| US-20070099880-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099880-A1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | CYP19A1 34/4885MAPT 99/4885MEN1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.